BioMedNewsBreaks

WednesdayOct 22, 2025 9:15 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances HyBryte(TM) as Potential First-Line CTCL Treatment with Promising FLASH Results 

Soligenix (NASDAQ: SNGX) is continuing to build momentum in the treatment of early-stage cutaneous T-cell lymphoma (“CTCL”) through promising results from its pivotal FLASH trial and ongoing FLASH 2 confirmatory study. HyBryte(TM)—a novel, non-UV light-activated therapy using synthetic hypericin—has demonstrated statistically significant efficacy and safety, offering hope in a field where therapeutic innovation has lagged. In the original FLASH study, nearly half of patients showed meaningful response at 18 weeks, and interim results from an independent University of Pennsylvania study reported a 75% response rate. FLASH 2 builds on these findings with improved design while addressing regulatory requirements for confirmatory…

Continue Reading

FridayOct 17, 2025 2:54 pm

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Unveils IzoView: A Game-Changing Platform for Next-Gen Breast Cancer Detection

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) is leading a transformation in breast cancer screening with its flagship IzoView Breast CT Imaging System, a next-generation technology designed to overcome the long-standing limitations of traditional mammography. Unlike compression-based 2D imaging, IzoView delivers true 360-degree, 3D visualization without discomfort, enabling clearer detection—especially in dense breast tissue, which often obscures lesions in standard scans. With a rapid 10-second scan time, high spatial resolution surpassing MRI, and radiation levels comparable to conventional mammography, the system streamlines diagnosis while enhancing patient safety and experience. Built as a scalable platform, IzoView supports future software-driven clinical applications—from screening…

Continue Reading

FridayOct 17, 2025 2:21 pm

BioMedNewsBreaks — Oncotelic Therapeutics Inc. (OTLC) Positioned to Fill Critical Gaps in Cancer Care with RNA and Small-Molecule Therapies

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed its efforts to pioneer RNA candidates and strategic programs aimed at some of the most lethal and overlooked cancers. “Immunotherapy and RNA-based approaches have begun to reshape the understanding of cancer treatment. The FDA approved 17 new immunotherapies in 2024 alone, spanning multiple cancer types and delivering breakthroughs such as checkpoint inhibitors and individualized vaccines. Yet despite this progress, significant unmet needs persist, particularly in rare pediatric cancers, resistant solid tumors and underserved population. Oncotelic is strategically positioned to fill gaps where traditional treatments fall short,” the article reads.…

Continue Reading

ThursdayOct 16, 2025 2:38 pm

BioMedNewsBreaks — NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Advances KETAFREE(TM), Expands Pipeline Targeting Urgent Needs

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, recently secured approval from the U.S. Food and Drug Administration (“FDA”) for its Suitability Petition to advance KETAFREE(TM), a preservative-free version of ketamine. “The ruling allows the company to re-file its Abbreviated New Drug Application (‘ANDA’) for the product, which it has now done, a key step in bringing it to market,” reads a recent article. “Currently, ketamine is sold in multidose vials that require preservatives to maintain sterility after repeated use. The most common additive, Benzethonium Chloride, is known to be toxic. NRx’s proposed alternative eliminates preservatives by using single-patient dosing,…

Continue Reading

ThursdayOct 16, 2025 1:55 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Combining Portability and Precision to Redefine Future of Cardiac Care

HeartBeam (NASDAQ: BEAT) was featured in a recent article that discussed its development of a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. “The importance of such innovation is underscored by the widespread impact of heart disease, such as heart rhythm problems… The VALID-ECG study results carry significant weight for both clinical adoption and HeartBeam’s commercialization pathway,” reads the article. “For HeartBeam, the upcoming commercialization of its ECG system represents more than a regulatory milestone; it is a potential step toward redefining how heart…

Continue Reading

WednesdayOct 15, 2025 11:33 am

BioMedNewsBreaks — Adageis CEO Discusses AI-Driven Solutions for Value-Based Care in Latest Bell2Bell Podcast 

Adageis, a healthcare technology company revolutionizing patient care through innovative digital solutions, is featured in the latest episode of The Bell2Bell Podcast, produced by IBN, a multifaceted communications organization connecting public companies with the investment community. In the interview, Adageis CEO Shane Speirs explains how the company’s AI-powered platform simplifies the administrative challenges of delivering value-based care by digitizing complex insurance and compliance processes. “We make it easy to see what measures practices need to hit and how to hit them for each individual patient,” Speirs said, noting that Adageis currently supports more than 580,000 patient lives. The conversation explores…

Continue Reading

WednesdayOct 15, 2025 11:05 am

BioMedNewsBreaks — Humacyte, Inc. (NASDAQ: HUMA) Announces $60 Million Registered Direct Offering of Common Stock and Warrants 

Humacyte (NASDAQ: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues, announced it has entered into a securities purchase agreement with fundamental institutional investors for an oversubscribed registered direct offering totaling approximately $60 million. The Company will issue 28,436,018 shares of common stock and accompanying warrants to purchase an equal number of shares at $2.11 per unit. The warrants become exercisable 180 days after issuance, carry an exercise price of $2.11 per share, and expire April 7, 2031. Gross proceeds are expected to total $60 million before fees and expenses, with closing anticipated on or about Oct.…

Continue Reading

TuesdayOct 14, 2025 3:49 pm

BioMedNewsBreaks — RADR(R) Platform Powers Lantern Pharma Inc.’s (NASDAQ: LTRN) Push Into Rare Pediatric Brain Cancer Treatment

Lantern Pharma (NASDAQ: LTRN) is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs. The company was featured in a recent article that discussed its preparation for the launch of a trial targeting a rare pediatric disease, planned for Q1 2026. This comes “in the wake of its optimistic meeting with the U.S. Food and Drug Administration (‘FDA’) to receive critical guidance on the company’s trial design and the FDA’s regulatory pathway… Lantern Pharma is developing its clinical trial with the hope of demonstrating the…

Continue Reading

TuesdayOct 14, 2025 2:21 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Updates U.S. Medical Advisory Board to Advance Phase 3 Development of HyBryte for CTCL 

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced updates to its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (CTCL) to support the ongoing Phase 3 development of HyBryte(TM) (synthetic hypericin). The board, comprised of leading dermatologic and oncologic experts, will provide strategic guidance as Soligenix advances regulatory and commercialization activities for its photodynamic therapy. President and CEO Christopher J. Schaber, PhD, said the addition of new key opinion leaders reinforces the program’s clinical depth and the company’s commitment to bringing HyBryte to CTCL patients worldwide. To view the full press release, visit https://ibn.fm/6ET3I…

Continue Reading

TuesdayOct 14, 2025 10:15 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Appoints Amanda L. Ferrio as Chief Financial Officer

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels, announced the promotion of Amanda L. Ferrio to Chief Financial Officer, succeeding Cecile Munnik, CPA/CA, following a transition period through the company’s Q3 2025 filing. Ferrio, who has over 15 years of accounting and finance experience, previously served as Vice President of Accounting & Finance at Progressive Care LLC, where she led financial reporting, budgeting, and SEC compliance. CEO David Phipps said her deep operational insight will support NextPlat’s focus on financial performance and sustainable shareholder value. To view…

Continue Reading